Login to Your Account

AACR 2012

Cancer Drug Combos Seek Bigger Bang, Longer Tail

By Anette Breindl
Science Editor

Monday, April 9, 2012

Targeted therapies and immunotherapies are in one sense opposites. Targeted therapies have high response rates and spectacular remissions, but those remissions are all too often short-lived, leading ultimately to a rather slim survival advantage.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription